Healthcare
AMRX Stock Analysis
Amneal Pharmaceuticals, Inc. · current price $17.52 (-2.72% today)
Solid setup — 4/4 EPS beats. Momentum, fundamentals and macro indicators are aligned.
★★★★
Quality
AMRX Stock AnalysisAmneal Pharmaceuticals, Inc. · current price $17.52 (-2.72% today)
Each pillar is scored 0-100 inside the stock’s own peer group, so a chipmaker is measured against chipmakers. These are quality descriptors, not buy or sell signals.
Reading AMRX’s price and volume history…
Checking the areas that decide this thesis…
AI-generated from the company’s own filings and recent coverage, and it can be incomplete or wrong. A PASS is a reading of the cited evidence, not a verified fact and not a reason to buy. Follow each citation to the source.
Reading AMRX’s filings…
| Quarter | EPS | Est. | Surprise | Result |
|---|---|---|---|---|
| 2025-09-30 | $0.17 | $0.14 | +22.9% | Beat |
| 2025-12-31 | $0.21 | $0.18 | +14.1% | Beat |
| 2026-03-31 | $0.27 | $0.17 | +59.6% | Beat |
| 2026-06-30 | $0.30 | $0.23 | +30.3% | Beat |
Amneal Pharmaceuticals, Inc. (AMRX) currently has a TickerMover Quant Score of 63/100, rated ★★★★ Quality. The Quant Score is a quantitative composite across six research pillars — momentum, quality, growth, valuation, sentiment and risk. It is research information, not investment advice.
TickerMover does not give buy or sell recommendations. AMRX scores 63/100 (★★★★ Quality) on our quantitative research model — a screening signal, not a personal recommendation. Do your own research, and consider an FCA-authorised adviser before investing.
AMRX's Quant Score and underlying data refresh through US market hours (about every five minutes), using public market and fundamental data.
Real-time scoring, conflict detection, Reverse DCF and peer comparison — free while in beta.
Open the dashboard for AMRX →
